However, acquisition of the p53 mutation R172H (equivalent to R175H in humans) was only seen to confer an advantage to cells after the induction of colitis by the administration of DSS, potentially reflecting the ability of p53 mutant cells to deal with colitis-associated reactive oxygen species (ROS) (Vermeulen et al. 2013). This evidence concerns the gene TP53 and colitis.